Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

A subset of patients with metastatic melanoma have sustained remissions following treatment with immune checkpoint inhibitors. However, analyses of pretreatment tumor biopsies for markers predictive of response, including PD-1 ligand (PD-L1) expression and mutational burden, are insufficiently preci...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xin, Sullivan, Ryan J., Kalinich, Mark, Kwan, Tanya Todorova, Giobbie-Hurder, Anita, Pan, Shiwei, LiCausi, Joseph A., Milner, John D., Nieman, Linda T., Wittner, Ben S., Ho, Uyen, Chen, Tianqi, Kapur, Ravi, Lawrence, Donald P., Flaherty, Keith T., Sequist, Lecia V., Ramaswamy, Sridhar, Miyamoto, David T., Lawrence, Michael, Toner, Mehmet, Isselbacher, Kurt J., Maheswaran, Shyamala, Haber, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2018
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877960/
https://www.ncbi.nlm.nih.gov/pubmed/29453278
http://dx.doi.org/10.1073/pnas.1719264115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877960/
https://www.ncbi.nlm.nih.gov/pubmed/29453278
http://dx.doi.org/10.1073/pnas.1719264115

Ejemplares similares